InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today issued an update as part of its product development, commercialization and revenue growth strategy. The company reported on its three business divisions and wholly owned subsidiaries, which include Vektor Pharma TF GmbH, 3a-diagnostics GmbH and XPhyto Laboratories. According to the update, Vektor Pharma is pursuing a scalable business strategy that focuses on development and commercialization of generic and hybrid-generic drug formulations, which present potential for lower development costs, lower regulatory risk and expedited pathways to market. The company’s 3a-diagnostics subsidiary’s portfolio includes “Covid-ID Lab,” a rapid point-of-care PCR test platform with a CE-mark (“CE-IVD”) approved for sale in Europe, and an oral dissolvable biosensor for ultra-low-cost self-testing, which is currently in product development. Further, XPhyto Laboratories is pursuing a multi-pronged approach to psychedelic medicine including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue engineering, and clinical validation. XPhyto Therapeutics plans to release a complete update and strategy on its psychedelic medicine program in the coming days.

To view the full press release, visit https://ibn.fm/PCo9Y

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.